Catalog No.
EHB86903
Expression system
Mammalian Cells
Species
Homo sapiens (Human)
Protein length
Met1-Ser378
Predicted molecular weight
67.31 kDa
Nature
Recombinant
Endotoxin level
Please contact with the lab for this information.
Purity
>90% as determined by SDS-PAGE.
Accession
NP_001333870.1
Applications
ELISA, Immunogen, SDS-PAGE, WB, Bioactivity testing in progress
Form
Lyophilized
Storage buffer
Lyophilized from a solution in PBS pH 7.4, 1mM EDTA, 4% Trehalose, 1% Mannitol.
Reconstitution
Reconstitute in sterile water for a stock solution.A copy of datasheet will be provided with the products, please refer to it for details.
Shipping
In general, proteins are provided as lyophilized powder/frozen liquid. They are shipped out with dry ice/blue ice unless customers require otherwise.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Alternative Names
HER1, Receptor tyrosine-protein kinase erbB-1, Proto-oncogene c-ErbB-1, Epidermal growth factor receptor, EGFR, ERBB1, ERBB
GLUT1 sensitizes tumor cells to EGFR-TKIs by binding with activated EGFR and regulating its downstream signaling pathways., PMID:40437580
The Prognostic Significance of Epidermal Growth Factor Receptor Amplification and Epidermal Growth Factor Receptor Variant III Mutation in Glioblastoma: A Systematic Review and Meta-Analysis with Implications for Targeted Therapy., PMID:40331985
Regulatory T cell depletion promotes myeloid cell activation and glioblastoma response to anti-PD1 and tumor-targeting antibodies., PMID:40280128
Epigenetically elevated RAD51AP1 regulates the RAD51-UAF1 complex contributing to temozolomide resistance in EGFRvIII glioblastoma., PMID:40211735
Design of immunogens to present a tumor-specific cryptic epitope., PMID:40175576
Expanding the Therapeutic Reach of Chimeric Antigen Receptor T-Cells and Bispecific T-Cell Engagers Across Solid Tumors., PMID:40138603
Engineering Multifunctional Peptide-Decorated Nanofibers for Targeted Delivery of Temozolomide across the Blood-Brain Barrier., PMID:40091203
A Cross-Sectional Exploratory Study of Rat Sarcoid (Ras) Activation in Women with and Without Polycystic Ovary Syndrome., PMID:40072105
Targeting adenosine enhances immunotherapy in MSS colorectal cancer with EGFRvIII mutation., PMID:39947814
In Silico Born Designed Anti-EGFR Aptamer Gol1 Has Anti-Proliferative Potential for Patient Glioblastoma Cells., PMID:39940838
Isolation and Characterization of the First Antigen-Specific EGFRvIII vNAR from Freshwater Stingray (Potamotrygon spp.) as a Drug Carrier in Glioblastoma Cancer Cells., PMID:39940647
Corticosteroid-Dependent Association between Prognostic Peripheral Blood Cell-Free DNA Levels and Neutrophil-Mediated NETosis in Patients with Glioblastoma., PMID:39887264
Efficient gene delivery admitted by small metabolites specifically targeting astrocytes in the mouse brain., PMID:39799395
Clinical progress in the development of CAR T cells to treat malignant glioma., PMID:39695004
Novel tri-specific T-cell engager targeting IL-13Rα2 and EGFRvIII provides long-term survival in heterogeneous GBM challenge and promotes antitumor cytotoxicity with patient immune cells., PMID:39622583
Self-assembled nanovaccine based on apoferritin: Development and vaccine regimen evaluation., PMID:39613269
Enhancing anti-EGFRvIII CAR T cell therapy against glioblastoma with a paracrine SIRPγ-derived CD47 blocker., PMID:39521782
Discovery of novel Macrocyclic small molecules Based on 2-Amino-4-thiazolylpyridineas selective EGFR inhibitors with high Blood-Brain barrier penetration for the treatment of glioblastoma., PMID:39476599
Expression features of targets for anti-glioma CAR-T cell immunotherapy., PMID:39467936
Expression of EGFRvIII and its co‑expression with wild‑type EGFR, or putative cancer stem cell biomarkers CD44 or EpCAM are associated with poorer prognosis in patients with hepatocellular carcinoma., PMID:39450530
Enhanced anti-tumor efficacy of electroporation (EP)-mediated DNA vaccine boosted by allogeneic lymphocytes in pre-established tumor models., PMID:39358555
PD1CD28 chimeric molecule enhances EGFRvⅢ specific CAR-T cells in xenograft experiments in mouse models., PMID:39352918
Enhanced Anticancer Activity of 7MeERT over Ertredin: A Comparative Study on Cancer Cell Proliferation and NDUFA12 Binding., PMID:39334963
Blood and cerebrospinal fluid biomarkers in neuro-oncology., PMID:39329301
EGFR and EGFRvIII coopt host defense pathways promoting progression in glioblastoma., PMID:39248287
Therapeutic Efficacy of IL7/CCL19-Expressing CAR-T Cells in Intractable Solid Tumor Models of Glioblastoma and Pancreatic Cancer., PMID:39240078
Formation of EGFRwt/EGFRvIII homo- and hetero-dimers in glioblastoma cells as detected by single molecule localization microscopy., PMID:39073345
A syngeneic spontaneous zebrafish model of tp53-deficient, EGFRvIII, and PI3KCAH1047R-driven glioblastoma reveals inhibitory roles for inflammation during tumor initiation and relapse in vivo., PMID:39052000
Pro-Oxidant Auranofin and Glutathione-Depleting Combination Unveils Synergistic Lethality in Glioblastoma Cells with Aberrant Epidermal Growth Factor Receptor Expression., PMID:39001381
CAR-T Cells Therapy in Glioblastoma: A Systematic Review on Molecular Targets and Treatment Strategies., PMID:39000281
Structural insights into the role and targeting of EGFRvIII., PMID:38908376
EGFRvIII Confers Sensitivity to Saracatinib in a STAT5-Dependent Manner in Glioblastoma., PMID:38892466
Synergistic effect of chimeric antigen receptor modified with Bcl-2 on enhanced solid tumour targeting., PMID:38878230
Malignant phyllodes tumor with EGFR variant III mutation: A rare case report with immunohistochemical and genomic studies., PMID:38850845
Multidisciplinary Management of Isocitrate Dehydrogenase-Mutated Gliomas in a Contemporary Molecularly Defined Era., PMID:38833641
Acidity-targeting transition-aided universal chimeric antigen receptor T-cell (ATT-CAR-T) therapy for the treatment of solid tumors., PMID:38759487
Bystander Effects, Pharmacokinetics, and Linker-Payload Stability of EGFR-Targeting Antibody-Drug Conjugates Losatuxizumab Vedotin and Depatux-M in Glioblastoma Models., PMID:38743766
Overexpressing Bcl-2 enhances murine chimeric antigen receptor T cell therapy against solid tumor., PMID:38691335
Principles in the Management of Glioblastoma., PMID:38674436
RNA splicing analysis deciphers developmental hierarchies and reveals therapeutic targets in adult glioma., PMID:38662454
Mesenchymal glioma stem cells trigger vasectasia-distinct neovascularization process stimulated by extracellular vesicles carrying EGFR., PMID:38570528
EGFR amplification and EGFRvIII predict and participate in TAT-Cx43266-283 antitumor response in preclinical glioblastoma models., PMID:38507464
Epidermal Growth Factor Receptor Inhibitors in Glioblastoma: Current Status and Future Possibilities., PMID:38396993
Enhancing CAR-T cell metabolism to overcome hypoxic conditions in the brain tumor microenvironment., PMID:38386420
Repeated peripheral infusions of anti-EGFRvIII CAR T cells in combination with pembrolizumab show no efficacy in glioblastoma: a phase 1 trial., PMID:38216766
[Immunotherapy against gliomas]., PMID:38169045
NDUFA12 as a Functional Target of the Anticancer Compound Ertredin in Human Hepatoma Cells As Revealed by Label-Free Chemical Proteomics., PMID:38104258
Frequency and functional characterization of fusion genes in squamous cell carcinoma of the lung., PMID:37981082
Blockage of EGFR/AKT and mevalonate pathways synergize the antitumor effect of temozolomide by reprogramming energy metabolism in glioblastoma., PMID:37920878
Immunohistochemical detection of EGFRvIII in glioblastoma - Anti-EGFRvIII antibody validation for diagnostic and CAR-T purposes., PMID:37918325
For research use only. Not for human or drug use.
